ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1203

Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis

Jürgen Wollenhaupt1, Jacques Morel2, Claire Daien3, Adeline Ruyssen-Witrand4, Cédric Lukas3, Christophe Richez5, Andrea Shapiro6, Douglass S Chapman7, Magali Cros8, Jose L Rivas9 and Gustavo Citera10, 1Struenseehaus Centre for Rheumatology and Clinical Immunology, Hamburg, Germany, 2Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, 3CHU Montpellier and University of Montpellier, Montpellier, France, 4Hôpital Purpan, CHU Toulouse, Toulouse, France, 5Groupe Hospitalier Pellegrin-CHU de Bordeaux, Bordeaux, France, 6Pfizer Inc, Peapack, NJ, 7Pfizer Inc, New York, NY, 8Pfizer Inc, Paris, France, 9Pfizer SLU, Madrid, Spain, 10Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina

Meeting: ACR Convergence 2020

Keywords: body mass, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 8, 2020

Session Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: A prior post hoc analysis of tofacitinib clinical trial data reported improvements in RA outcomes with tofacitinib vs placebo (PBO) through Month (M)6, regardless of baseline (BL) BMI.1 This post hoc analysis assessed change from BL (∆) in BMI, and disease activity by BL BMI status, in patients (pts) with moderate/severe RA receiving tofacitinib through M12.

Methods: Data were pooled from Phase 3 and 3b/4 studies of pts who were MTX-naïve (NCT01039688), or inadequate responders to conventional synthetic (cs) or biologic DMARDs (NCT00960440; NCT00847613; NCT00814307; NCT00856544; NCT00853385; NCT02187055; NCT02831855). Pts received ≥ 1 dose of tofacitinib 5 or 10 mg twice daily (BID), or 11 mg once daily (QD), alone or with background csDMARDs, or PBO. Least squares (LS) mean ∆BMI (linear mixed model repeated measures; observed cases) was summarized for all treatment groups at M3/6/12 (M3/6 only for tofacitinib 11 mg QD and PBO). Other assessments at M3/6/12 included ∆BMI +/‑ BL concomitant glucocorticoids (GC) or antidepressants (descriptive statistics only), LS mean ∆DAS28‑4(ESR), stratified by BL BMI status (< 25, ≥ 25 – < 30, ≥ 30), and correlations between LS mean ∆BMI and ∆DAS28‑4(ESR).

Results: In total, 2,349, 1,611, 694, and 681 pts received tofacitinib 5 mg BID, 10 mg BID, 11 mg QD, or PBO, respectively. Demographics and baseline characteristics were generally similar across treatment groups, except in pts receiving tofacitinib 11 mg QD, where some differences were observed in gender, race, and concomitant GC use (Table 1). At M3/6, LS mean BMI significantly increased from BL with all tofacitinib doses vs PBO (all p< 0.05); ∆BMI was greatest with 10 mg BID, and lowest with 11 mg QD (Figure 1a). LS mean ∆BMI was greater in pts receiving tofacitinib as monotherapy vs combination therapy at M3/6/12 (Figure 1b). ∆BMI was generally similar in pts receiving treatment +/‑ concomitant GCs or antidepressants (data not shown). Improvements in DAS28‑4(ESR) scores were observed in each BL BMI status group at M3/6/12, and were greatest with all tofacitinib doses vs PBO. LS mean ∆DAS28‑4(ESR) was generally numerically highest for pts with BMI < 25 and numerically lowest for pts with BMI > 30, for all tofacitinib doses. LS mean ∆DAS28‑4(ESR) was also generally greatest with tofacitinib 10 mg BID and 11 mg QD vs 5 mg BID across BL BMI status groups (Figure 1c). Across treatment groups, model-adjusted associations between ∆DAS28-4(ESR) scores and ∆BMI were weak (correlation coefficients all < 0.3; Table 2).

Conclusion: ∆BMI was greater with tofacitinib (all doses) vs PBO at M3/6, and with tofacitinib monotherapy vs combination therapy at M3/6/12. Improvements in DAS28‑4(ESR) were seen across all BL BMI status groups. BMI increases with tofacitinib were only weakly associated with DAS28-4(ESR) improvements. The relationship between disease activity and ∆BMI requires further investigation.

  1. Dikranian A et al. Arthritis Rheumatol 2018; 69 (suppl 10).

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by Anthony G. McCluskey, CMC Connect, and funded by Pfizer Inc.


Disclosure: J. Wollenhaupt, Pfizer Inc, 5, 8; J. Morel, AbbVie, 5, Bristol-Myers Squibb, 2, 5, Eli Lilly, 5, Novartis, 5, Pfizer Inc, 2, 5, Sanofi, 5; C. Daien, AbbVie, 2, Abivax, 5, Bristol-Myers Squibb, 2, Eli Lilly, 2, MSD, 2, Novartis, 2, Pfizer Inc, 2, Roche-Chugaï, 2, Sandoz, 2; A. Ruyssen-Witrand, None; C. Lukas, None; C. Richez, None; A. Shapiro, Pfizer Inc, 1, 3; D. Chapman, Pfizer Inc, 1, 3; M. Cros, Pfizer Inc, 1, 3; J. Rivas, Pfizer Inc, 1, 3; G. Citera, AbbVie, 5, 8, Eli Lilly, 5, 8, Bristol-Myers Squibb Company, 5, 8, Gema, 5, 8, Pfizer, 5, 8, Janssen, 5, 8.

To cite this abstract in AMA style:

Wollenhaupt J, Morel J, Daien C, Ruyssen-Witrand A, Lukas C, Richez C, Shapiro A, Chapman D, Cros M, Rivas J, Citera G. Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/analysis-of-the-impact-of-tofacitinib-treatment-on-weight-in-patients-with-rheumatoid-arthritis/. Accessed January 22, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-the-impact-of-tofacitinib-treatment-on-weight-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.